Secukinumab, a new anti-IL17A biologic therapy, induces rapid and durable clinical, histological, and molecular resolution of psoriasis plaques over 1 year of administration
EXPERIMENTAL DERMATOLOGY（2016）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要